NOV 2 6 2004 DE

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information untess it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known		
				Application Number	10/777883	
IN	IFORMATION	ON DIS	CLOSURE	Filing Date	February 12, 2004	
S	STATEMENT BY APPLICANT			First Named Inventor	Alexander V. Chervonsky	
				Art Unit	1614	
	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	JMY-P01-001	

	U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (#known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
25	A1	6,153,441	11/28/00	Appelbaum, et al.	
1	I	[

	FOREIGN PATENT DOCUMENTS					
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
Initials* No.1	Country Code ³ -Number ⁴ -Kind Code ⁸ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	70	
45	B1	WO 92/01810	2/6/92	Michael Lemer		П
18	B2	WO 02/20615 A2	3/14/02	MICROMET AG		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nich indication of the year of the reign of the Emperor must precede the serial number of the patent document. Indication of the year of the reign of the Emperor must precede the serial number of the patent document. Indication of the year of the reign of the Emperor must precede the serial number of the patent document. Indication of the year of the reign of the Emperor must precede the serial number of the patent document. Indication of the year of the reign of the Emperor must precede the serial number of the patent document. Indication of the year of the reign of the Emperor must precede the serial number of the patent document. In the year of the reign of the Emperor must precede the serial number of the patent document. In the year of the reign of the Emperor must precede the serial number of the patent document. In the year of the reign of the Emperor must precede the serial number of the patent document. In the year of the reign of the Emperor must precede the serial number of the patent document. In the year of the reign of the Emperor must precede the serial number of the patent document. In the year of the reign of the Emperor must precede the serial number of the year of the reign of the Emperor must precede the serial number of the year of the reign of the year of

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
22	C1	Baekkevold et al., "The CCR7 ligand ELC (CCL19) is transcytosed in high endothelial venules and mediates T cell recruitment," J. Exp. Med. 193:1105-1111, 2001.	
35	C2	Baggiolini et al., "Human Chemokines: An Update," Annu. Rev. Immunol. 15:675-705, 1997.	
25	СЗ	Campbell et al., "Chemokines and the arrest of lymphocytes rolling under flow conditions," Science, 279:381-384, 1998.	
)1	C4	Chen et al., "Ectopic expression of the murine chemokines CCL21a and CCL21b induces the formation of lymph node-like structures in pancreas, but not skin, of transgenic mice," J. Immunol., 168:1001-1008, 2002.	
SI	C5	Constantin et al., "Chemokines trigger immediate beta 2 integrin affinity and mobility changes: differential regulation and roles in lymphocyte arrest under flow," Immunity, 13:759-769, 2000.	
55	C6	Delovitch et al., "The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD," Immunity, 7:727-738, 1997.	
28	C7	Elices et al., "VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site, " Cell 60:577-584, 1990.	
25	C8	Fan et al., "Cutting edge: ectopic expression of the chemokine TCA4/SLC is sufficient to trigger lymphoid neogenesis," J. Immunol., 164:3955-3959, 2000.	
٢(C9	Gunn et al., "Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization," J. Exp. Med., 189:451-460, 1999.	
3)	C10	Hjelmstrom et al., "Lymphoid tissue homing chemokines are expressed in chronic inflammation," Am. J. Pathol., 156:1133-1138, 2000.	
ζζ	C11	Kreisel et al., "Nonhematopoietic allograft cells directly activate CD8* T cells and trigger acute rejection: an alternative mechanism of allorecognition," Nat. Med., 8:233-239, 2002.	
35	C12	Limmer et al, " Efficient presentation of exogenous antigen by liver endothelial cells to CD8* T cells results in antigen-specific T-cell tolerance," Nat. Med. 12:1348-1354, 2000.	
11	C13	Luther et al., "BLC expression is pancreatic islets causes B cell recruitment and lymphotoxin-	

PTC/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Spord to a collection of information units it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known		
				Application Number	10/777883	
INI	FORMATI	ON DIS	CLOSURE	Filing Date	February 12, 2004	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Alexander V. Chervonsky	
				Art Unit	1614	
(Use as many sheets as necessary)			iecessary)	Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number	JMY-P01-001	

		dependent lymphoid neogenesis," Immunity, 12:471-481, 2000.	
ج\$	C14	Ngo et al., "Epstein-Barr virus-induced molecule 1 ligand chemokine is expressed by dendritic cells in lymphoid tissues and strongly attracts naive T cells and activated B cells," J. Exp. Med., 188:181-191, 1998.	
ŞŜ	C15	Pober et al., "Human endothelial cell presentation of antigen and the homing of memory/effector T cells to skin," Ann. NY Acad. Sci. 941:12-25.	
21	C16	Savinov et al., "Presentation of antigen by endothelial cells and chemoattraction are required for homing of insulin-specific CD8+ T cells," J. Exp. Med. 197:643-656, 2003.	
SS	C17	Sebastiani et al., "Chemokine receptor expression and function in CD4* T lymphocytes with regulatory activity," J. Immunol. 166:996-1002, 2001.	
<i>S</i> 2	C18	Serreze, et al., "Major histocompatibility complex class I-deficient NOD-B2m mice are diabetes and insulitis resistant," Diabetes, 43:505-509, 1994.	
ςς	C19	Shimizu et al., "Regulated expression and binding of three VLA (beta 1) integrin receptors on T cells," Nature, 345:250-253, 1990.	
٤	C20	Stein et al., "The CC chemokine thymus-derived chemotactic agent 4 (TCA-4, secondary lymphoid tissue chemokine, 6Ckine, exodus-2) triggers lymphocyte function-associated antigen 1-mediated arrest of rolling T lymphocytes in peripheral lymph node high endothelial venules," J. Exp. Med., 191:61-75, 2000.	,
3	C21	Tisch et al., "Insulin-dependent diabetes mellitus," Cell 85:291-297, 1996.	
22 22 23	C22	Toyoda et al., "Contribution of T cells to the development of autoimmune diabetes in the NOD mouse model," BioEssays, 20:750-757, 1998.	
	C23	Valujskikh et al., "Cross-primed CD8" T cells mediate graft rejection via a distinct effector pathway," Nat. Immunol., 3:844-851, 2002.	
55	C24	von Andrian et al., "T-cell function and migration. Two sides of the same coin." N. Engl. J. Med., 343:1020-1034, 2000.	
57	C25	Wong et al., "Analysis of structure and function relationships of an autoantigenic peptide of insulin bound to H-2K ^d that stimulates CD8 T cells in insulin-dependent diabetes mellitus," PNAS, 99:5551-5556, 2002.	
25	C26	Wong et al., "CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells," J. Exp. Med., 183:67-76, 1996.	
32	C27	Wong et al., "Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library," Nat. Med., 5:1026-1031, 1999.	
21	C28	Wong et al., "The role of CD4 vs. CD8 T cells in IDDM," J. Autoimmune., 13: 290-295, 1999.	
2	C29	Yoshie et al., "Novel lymphocyte-specific CC chemokines and their receptors," J. Leukocyte Biol. 62:634-644, 1997.	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{&#}x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.